Segluromet is an anti-diabetic drug owned by Merck Sharp Dohme. The drug, which contains Ertugliflozin and Metformin Hydrochloride, became available on the market on 19 December, 2017. It is sold in tablet form for oral administration.
The generic versions of Segluromet are expected to be released after 21 October, 2030, with the last patent expiry date. This is dependent on whether there are any legal obstacles or additional patents that would delay a generic introduction. Stay tuned for updates on the Segluromet generic release.
Segluromet is used as an adjunct to diet and exercise to manage blood sugar levels in adults with type 2 diabetes. The drug's active ingredients, Ertugliflozin and Metformin Hydrochloride, contribute to its efficacy by reducing glucose production and improving the body's response to insulin.
Segluromet holds three patents, all related to the chemical formulation of its active ingredients. The last of these patents expires on 21 October, 2030. Below are the details of the patent: